Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofersen CNS distribution study in healthy adults
NCT03764488Phase 1Completed
- Sponsor
- Biogen
- Start
- Dec 2018
- Primary completion
- Jun 2021
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, open-label trial of tofersen in amyotrophic lateral sclerosis (ALS) (4 arms), sponsored by Biogen. Primary endpoint: BIIB067 Concentrations Throughout the CNS. Started Dec 2018; status: completed.
02
Drugs
tofersen
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03764488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03764488.